X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, which is under phase 3 clinical development for the treatment of eschar, in patients with deep partial- and/or full-thickness thermal burns.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
The collaboration aims for the promotion of NexoBrid (anacaulase-bcdb), a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in Germany, Austria, Belgium, the Netherlands and Luxemburg.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: PolyMedics Innovations
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 08, 2023
Details:
EscharEx (EX-02) is being evaluated for efficacy and safety in the debridement of chronic wounds, with the first indication being VLUs. During debridement phase, 3M’s two-layer compression systems will be used as soc in all study arms, until the wounds reach complete healing.
Lead Product(s): EX-02
Therapeutic Area: Podiatry Product Name: EscharEx
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: 3M Health Care
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 11, 2023
Details:
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
The funding will be used to develop NexoBrid (anacaulase-bcdb), a topically administered biological product that enzymatically removes nonviable burn tissue, as a non-surgical solution for field-care burn treatment for the U.S. Army.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Department of Defense
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 26, 2023
Details:
NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
Under the collaboration, Mölnlycke will provide Mepilex® Up, its most recent line extension to its global market leading brand, along with Exufiber® and Exufiber® Ag dressings to be used during MediWound's upcoming Phase III study of EscharEx (EX-02) in venous leg ulcers.
Lead Product(s): EX-02
Therapeutic Area: Podiatry Product Name: EscharEx
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Molnlycke Health Care AB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 15, 2023
Details:
Under the collaboration, MIMEDX will provide its market leading placental tissue allograft EPIFIX® to be used during the wound healing phase of the EscharEx® (concentrate of proteolytic enzymes enriched in bromelain) Phase III study in venous leg ulcers (VLUs).
Lead Product(s): Bromelain Enriched Proteolytic Enzyme,Dehydrated Human Amnion Membrane
Therapeutic Area: Podiatry Product Name: EscharEx
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: MiMedx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 15, 2023
Details:
NexoBrid® (concentrate of proteolytic enzymes enriched in bromelain) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
Lead Product(s): Anacaulase-bcdb
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
